Lilly’s Omvoh Shows 27.7% Disease Control Among Ulcerative Colitis Responders

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz) met a one-year disease-control measure in 27.7% of ulcerative colitis patients who responded to induction treatment, while 20.4% of Crohn’s patients achieved corticosteroid-free deep remission.

In the LUCENT-2 maintenance analysis, the ulcerative colitis rate was 27.7% for patients who had responded to Omvoh during LUCENT-1 induction and were then rerandomized. The rate was 14% among patients assigned to placebo. The measure required clinical and histologic remission, fecal calprotectin of 250 μg/g or lower, and no corticosteroid use for at least 12 weeks before Week 52.

In the VIVID-1 Crohn’s disease analysis, 20.4% of patients taking Omvoh achieved clinical and endoscopic remission with no corticosteroid use during the 12 weeks before Week 52. The placebo rate was 2%. Both results came from post hoc analyses of Phase 3 trial data.

Among patients with prior biologic failure, the rates were 23.4% on Omvoh and 9.4% on placebo for ulcerative colitis. For Crohn’s disease, the rates were 15.7% and 0%, respectively.

The Crohn’s analysis is scheduled for presentation Sunday, Oct. 18, at UEG Week in Barcelona. Omvoh is approved in the United States for adults with moderately to severely active ulcerative colitis and Crohn’s disease.